Century Therapeutics Stock Price, News & Analysis
Company Description
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to address autoimmune diseases and cancer. According to the company’s public statements, its pipeline is built on an iPSC cell foundry and proprietary immune evasion engineering technology known as Allo-Evasion™, which is designed to enable off-the-shelf cell therapies that can be manufactured in advance and supplied to multiple patients.
Business focus and technology platform
Century Therapeutics describes itself as a clinical-stage biotechnology company that leverages expertise in cellular reprogramming, genetic engineering and manufacturing to create genetically engineered, iPSC-derived cell therapies. Its programs are designed to address B-cell-mediated autoimmune diseases, B‑cell malignancies and other high-impact diseases. The company’s Allo-Evasion™ technology is intended to provide immune evasion from T cells, natural killer (NK) cells and humoral immunity, supporting the development of allogeneic, off-the-shelf products.
The company reports that its iPSC cell foundry and manufacturing know-how are aimed at producing consistent cell therapy products at scale. Across multiple public disclosures, Century Therapeutics emphasizes that its approach is intended to offer advantages over existing cell therapies and expand patient access by moving away from patient-specific (autologous) manufacturing toward standardized allogeneic products.
Key pipeline programs
Century Therapeutics highlights several named investigational programs within its pipeline:
- CNTY-101: An iPSC-derived allogeneic CD19-targeting CAR-NK product being evaluated in autoimmune disease. The company has described CNTY‑101 as exhibiting B‑cell depletion in preclinical work and as the focus of the CALiPSO‑1 company-sponsored Phase 1 trial in B‑cell-mediated autoimmune diseases, as well as the CARAMEL investigator-initiated Phase 1/2 trial in similar indications.
- CNTY-308: A CD19-targeted CD4+/CD8+ αβ CAR‑iT cell therapy engineered with Allo‑Evasion™ 5.0. Century Therapeutics states that CNTY‑308 is being developed as a potential treatment for B‑cell-mediated diseases, and that it is advancing through Investigational New Drug (IND)-enabling studies to support planned clinical studies.
- CNTY-813: An iPSC-derived beta islet cell program for Type 1 diabetes (T1D). The company describes CNTY‑813 as comprising beta islets engineered with Allo‑Evasion™ 5.0, designed to protect against T cell, NK cell and humoral immune rejection, with the goal of durable glycemic control without chronic systemic immunosuppression. Century Therapeutics has reported preclinical data showing rapid and sustained normalization of glucose in diabetic mouse models, human C‑peptide production, and glucose-stimulated insulin secretion consistent with mature beta cell phenotypes.
- CNTY-341 and additional oncology programs: Century Therapeutics has disclosed early-stage development of CNTY‑341, a CD19/CD22 dual-targeted CAR‑iT investigational cell therapy intended for B‑cell malignancies, as well as a first solid tumor CAR‑iT program using a nectin‑4 CAR and other validated targets. These programs are described as being anchored by advanced iPSC-derived “tunable” CD4+/CD8+ αβ T cells and engineered with Allo‑Evasion™ 5.0.
Allo-Evasion™ 5.0 and immune evasion strategy
Century Therapeutics provides specific detail on its Allo‑Evasion™ 5.0 technology. In the company’s description, this engineering strategy includes knockout of human leukocyte antigen (HLA) class I and II, expression of a CD300a-based pan‑NK inhibitory ligand, and an immunoglobulin-degrading enzyme that reduces antibody-dependent cellular cytotoxicity (ADCC). These modifications are intended to protect iPSC-derived products from T‑cell, NK‑cell and antibody-mediated rejection, preserving cell survival in NK cytotoxicity and ADCC assays.
For its beta islet program, Century Therapeutics reports that Allo‑Evasion™ 5.0‑engineered iPSC-derived beta islets demonstrated resistance to NK cell-mediated killing and antibody-dependent cellular cytotoxicity in preclinical testing. For CNTY‑308 and other immune effector programs, the company has presented data indicating that Allo‑Evasion™ 5.0 can provide meaningful protection from allogeneic immune cells and antibody-mediated rejection.
Therapeutic areas and indications
Across its public communications, Century Therapeutics consistently identifies two main therapeutic areas:
- Autoimmune diseases: The company is developing CNTY‑101 and CNTY‑308 as potential treatments for B‑cell-mediated autoimmune diseases. It has highlighted preclinical and emerging clinical data showing B‑cell depletion and has discussed the potential for these programs in B cell-driven autoimmune conditions. The CALiPSO‑1 and CARAMEL trials are focused on autoimmune indications.
- Oncology (cancer): Century Therapeutics states that its pipeline includes iPSC-derived CAR‑NK and CAR‑T cell programs for B‑cell malignancies and solid tumors. It has presented data on CAR‑iT and CAR‑iNK cells designed to withstand the immunosuppressive tumor microenvironment, as well as dual-targeted and nectin‑4–based CAR‑iT programs.
In addition, the company has described a non-immune cell therapy program engineered with Allo‑Evasion™ 5.0, leveraging its selective iPSC differentiation expertise in high-impact therapeutic areas. The iPSC-derived beta islet program CNTY‑813 for Type 1 diabetes is the first disclosed example of a non-immune effector cell program.
Manufacturing and iPSC cell foundry
Century Therapeutics emphasizes that its therapies are derived from an iPSC cell foundry and that it has developed manufacturing processes, including a suspension bioreactor process, to generate mature, functional cells at scale. For the beta islet program, the company reports that this bioreactor process can deliver mature, functional beta islets suitable for scalable production. In broader disclosures, Century Therapeutics has highlighted the goal of achieving “antibody-like” scale for iPSC-derived cell therapies, indicating a focus on reproducible, large-scale production.
The company links its manufacturing approach to its stated objective of expanding patient access to cell therapies and addressing supply and development risks associated with earlier-generation cell therapies. By using iPSC-derived allogeneic products, Century Therapeutics aims to produce standardized lots that can be stored and distributed rather than manufactured individually for each patient.
Capital markets activity and listing status
Century Therapeutics’ common stock trades on Nasdaq under the ticker symbol IPSC. The company has disclosed that it is an emerging growth company under U.S. securities regulations. In an 8‑K filing, Century Therapeutics reported receiving a Nasdaq deficiency letter related to the minimum bid price requirement and noted that its listing was transferred from The Nasdaq Global Select Market to The Nasdaq Capital Market, while continuing to trade under the IPSC symbol. The company outlined its intention to consider options, including a potential reverse stock split, to regain compliance with Nasdaq’s bid price rule, while acknowledging that there can be no assurance of regaining compliance.
Century Therapeutics has also reported entering into a private placement with institutional accredited investors, issuing common stock, pre-funded warrants and common warrants. According to its 8‑K and accompanying press release, the company expects to use the net proceeds from this private placement to fund development of its lead product candidate, CNTY‑813, and for working capital and other general corporate purposes.
Financial reporting and collaboration history
Through its quarterly financial results press releases and related 8‑K filings, Century Therapeutics provides updates on its cash position, operating expenses and net income or loss. The company has reported research and development and general and administrative expenses associated with advancing its clinical and preclinical programs, as well as impairment charges and other items. It has also disclosed that collaboration revenue recognized in one period was associated with a collaboration, option and license agreement with Bristol‑Myers Squibb, and that this collaboration agreement was terminated, leading to recognition of remaining deferred revenue in that quarter.
In these filings, Century Therapeutics provides estimates of its cash runway based on its cash, cash equivalents and investments, and describes efforts to align its organizational structure and workforce with its prioritized pipeline, including a workforce reduction intended to focus resources on programs with the highest potential for what it describes as transformational value.
Corporate governance and organizational updates
The company’s 8‑K filings also document changes in its board of directors and executive leadership. Century Therapeutics has reported appointments of new directors with backgrounds in life science investment, corporate development and biotechnology leadership, as well as the resignation of a director. It has also disclosed changes in executive roles, including the appointment of its Chief Executive Officer as Board Chair and the departure of certain executives in connection with organizational changes, along with the designation of an interim principal financial officer.
These governance and organizational updates are presented by the company as part of its efforts to support its strategic focus on iPSC-derived cell therapy programs in autoimmune disease, oncology and Type 1 diabetes.
Research presentations and scientific visibility
Century Therapeutics regularly participates in scientific and investor conferences. The company has announced presentations at events such as the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, the European Alliance of Associations for Rheumatology (EULAR) Congress, and healthcare investment conferences. At these meetings, Century Therapeutics has presented data on its preclinical pipeline, including CAR‑iT and CAR‑iNK programs, Allo‑Evasion™ 5.0, and iPSC-derived beta islets, as well as clinical and translational data supporting CNTY‑101 and CNTY‑308.
Through these presentations, the company highlights technical aspects of its platform, such as generation of allogeneic iPSC-derived CD4+/CD8+ αβ CAR‑T cells with in vivo proliferation and tumor control comparable to primary T cells, and the ability of CNTY‑101 and CNTY‑308 to deplete B cells in preclinical models.